Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Safety and Effectiveness of the TENEO 317 Model 2 (1.28 US) Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Hyperopia With or Without Astigmatism

← catalyst calendar

NCT05264623 · readout in 93 d

Sponsored by Bausch & Lomb Incorporated (industry) · BLCO — their whole pipeline →.

Phase
Not applicable
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
140actual
Sites
9
Country
United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2022-11-15actualWhen the study began enrolling
Primary completion2026-11-20estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completion2026-11-20estimatedThe whole study's end, after follow-up
First posted2022-03-03actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-01-23actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Hyperopia

Intervention

  • Device: TENEO 317 Model 2 excimer laser

Primary outcomes

what the primary-completion date above is the date OF
The percentage of eyes with Uncorrected Distance Visual Acuity (UDVA) of 20/40 or better at the time of refractive stability
measured Up to 12 months
The percentage of eyes with Manifest Refractive Spherical Equivalent (MRSE) within 0.50 Diopter of intended correction at the time of refractive stability
measured Up to 12 months
The percentage of eyes with Manifest Refractive Spherical Equivalent (MRSE) within 1.00 Diopter of intended correction at the time of refractive stability
measured Up to 12 months

Permalink · BLCO's whole pipeline · Catalyst calendar · Every registered study · What changed